Immunic, Inc. (NasdaqCM: IMUX)
Health Care · Biotechnology · US
$16.52
+0.61% today · +87.3% 1Y
Immunic, Inc. (NasdaqCM: IMUX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $224.04M and employs 95 people.
Over the last twelve months the share price has gained 87.3%, trading between 5.06 and 17.43.
Tweenvest scores Immunic, Inc. across four factors: quality 26/100. Its strongest factor is quality.
IMUX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $224.04M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.00
- Dividend yield
- —
- Beta (5Y)
- 1.40
- 52-week high
- $17.43
- 52-week low
- $5.06
- Avg volume (3M)
- —
- Shares outstanding
- 13.64M
- Employees
- 95
- Next earnings
- —
About Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
- ISIN
- US4525EP2001
- Founded
- 2016
- Listed since
- Apr 17, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.40 | -1.65% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.29 | +0.01% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $149.00 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.77 | -0.38% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.75 | -1.18% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.70 | -7.01% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.